Dr. Xiaoyan Jiang is a Distinguished Scientist at the Terry Fox Laboratory of the BC Cancer, a Professor in the Department of Medical Genetics and an Associate Member of the Division of Hematology and Experimental Medicine, the Department of Medicine at the University of British Columbia. She is also an Adjunct Professor at the Shanghai Institute of Medical Genetics of the Shanghai Jiao Tong University and Soochow University. Dr. Jiang received her MD from Shanghai Second Medical University and her PhD, with Dr. Paul Jolicoeur, at McGill University. She then undertook post-doctoral training with Dr. Connie Eaves, at the BC Cancer Agency. Her research interests are focused on basic and translational research of molecular properties of leukemic stem cells that contribute to the development of leukemia and drug resistance, and she has pioneered local efforts to develop new therapeutic approaches to directly target these critical cells. 

Main Research Interests: 

  • Basic and translational leukemia research
  • Leukemic stem cell biology
  • Drug resistance
  • Gene regulation and proteome dynamics
  • Oncolytic virotherapy and immunotherapy
  • Nonviral gene therapy

The overall goal of Dr. Jiang's research program is to understand the molecular mechanisms and cellular functions of specific oncogenes, tumor suppressor genes, miRNAs/target genes, and their associated pathways/networks, in the regulation of the properties of cancer/leukemic stem cells, signal transduction events, metabolism/mitochondria vulnerabilities, immune responses and initiation and progression of human leukemia and drug resistance. The ultimate objective is to identify and characterize key druggable molecules and pathways, using our well-established in vitro and patient-derived xenotransplantation (PDX) models, which will lead to new, rationally designed, more effective, and less toxic, personalized anti-cancer therapies. In particular, Dr. Jiang and her lab are extremely interested in developing mechanism-based combination therapeutic strategies that can directly target drug-insensitive leukemic stem cells and mutated drug-resistant cells, to improve outcomes in leukemia patients, especially those destined to develop drug resistance.

  • Professor, Medical Genetics, University of British Columbia
  • Associate Member, Medicine, University of British Columbia
  • Associate Member, Experimental Medicine, University of British Columbia
  • Associate Member, Interdisciplinary Oncology Program, University of British Columbia
  • Adjunct Professor, Shanghai Institute of Medical Genetics, Shanghai Jiaotong University
  • Michael Smith Foundation for Health Research Scholar
  • MD, Shanghai Second Medical University
  • PhD, Division of Experimental Medicine, Faculty of Medicine, McGill University

Selected Publications

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Journal of the National Cancer Institute, 2013
Chen, Min, Gallipoli, Paolo, DeGeer, Donna, Sloma, Ivan, Forrest, Donna L, Chan, Matthew, Lai, Damian, Jorgensen, Heather, Ringrose, Ashley, Wang, Hui Mi, Lambie, Karen, Nakamoto, Helen, Saw, Kyi Min, Turhan, Ali, Arlinghaus, Ralph, Paul, James, Stobo, Jon, Barnett, Michael J, Eaves, Allen, Eaves, Connie J, Holyoake, Tessa L, Jiang, Xiaoyan
Back to top